Androgen action in prostate function and disease.

about

Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers

P2860

Q57107504-D4048484-484F-407A-9829-A9322D8C6A1D Q58587207-8CED49B2-3D7A-4896-948D-F7DDD52B8B66

P2860

Androgen action in prostate function and disease.

Item

http://www.wikidata.org/entity/Q55251761

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Androgen action in prostate function and disease.

@en

Androgen action in prostate function and disease.

@nl

type

Item

label

Androgen action in prostate function and disease.

@en

Androgen action in prostate function and disease.

@nl

prefLabel

Androgen action in prostate function and disease.

@en

Androgen action in prostate function and disease.

@nl

P1476

Androgen action in prostate function and disease.

@en

P2093

Barry R Zirkin

http://www.w3.org/2001/XMLSchema#string

Partha P Banerjee

http://www.w3.org/2001/XMLSchema#string

Subhadra Banerjee

http://www.w3.org/2001/XMLSchema#string

Terry R Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.

Testosterone and benign prostatic hyperplasia

Emerging therapies in castration resistant prostate cancer

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

P304

62-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29666834

http://www.w3.org/2001/XMLSchema#string

P932

5902724

http://www.w3.org/2001/XMLSchema#string

Androgen action in prostate function and disease.

about

P2860

P2860

Androgen action in prostate function and disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932